Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib

Clinical Pharmacology and Therapeutics
Y JinW Landschulz

Abstract

To assess the safety, tolerability, and pharmacology of LY3023703, a microsomal prostaglandin E synthase 1 (mPGES1) inhibitor, a multiple ascending dose study was conducted. Forty-eight subjects received LY3023703, celecoxib (400 mg), or placebo once daily for 28 days. Compared with placebo, LY3023703 inhibited ex vivo lipopolysaccharide-stimulated prostaglandin E2 (PGE2 ) synthesis 91% and 97% on days 1 and 28, respectively, after 30-mg dosing, comparable to celecoxib's effect (82% inhibition compared to placebo). Unlike celecoxib, which also inhibited prostacyclin synthesis by 44%, LY3023703 demonstrated a maximal increase in prostacyclin synthesis of 115%. Transient elevations of serum aminotransferase were observed in one subject after 30-mg LY3023703 dosing (10× upper limit of normal (ULN)), and one subject after 15-mg dosing (about 1.5× ULN). Results from this study suggest that mPGES1 inhibits inducible PGE synthesis without suppressing prostacyclin generation and presents a novel target for inflammatory pain.

References

Sep 15, 1987·Thrombosis Research·F Catella, G A FitzGerald
Oct 1, 1986·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner
Apr 9, 1969·Journal of the American Chemical Society·M Hamberg, B Samuelsson
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·B F McAdamG A FitzGerald
May 14, 2004·The Journal of Biological Chemistry·Daisuke KameiIchiro Kudo
Jan 26, 2005·Archives of Internal Medicine·James R SowersUNKNOWN Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators
Feb 16, 2005·Archives of Internal Medicine·Tai-Juan AwHenry Krum
Sep 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Miao WangGarret A FitzGerald
Apr 29, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Jun-ichi KawabeNaoyuki Hasebe
Jun 10, 2010·Circulation·Yiqun HuiGarret A FitzGerald
Jan 21, 2012·The Journal of Pharmacology and Experimental Therapeutics·Melania DovizioPaola Patrignani
May 4, 2012·Science Translational Medicine·Ying YuGarret A FitzGerald

❮ Previous
Next ❯

Citations

Apr 12, 2016·Trends in Pharmacological Sciences·Avijit DeyJianxiong Jiang
Jan 23, 2016·Journal of Medicinal Chemistry·Andreas KoeberleOliver Werz
Nov 15, 2016·Expert Opinion on Investigational Drugs·Sabine GröschGerd Geisslinger
Dec 23, 2016·Medicinal Research Reviews·Catarina Pereira-LeiteSalette Reis
Jun 10, 2017·Nature Reviews. Drug Discovery·Ajay S YekkiralaClifford J Woolf
Jun 20, 2017·Expert Opinion on Therapeutic Patents·Anastasia PsarraGeorge Kokotos
Apr 18, 2019·The Journal of Pharmacology and Experimental Therapeutics·Lihong ChenGarret A FitzGerald
Nov 7, 2019·Cardiovascular Research·Nicholas S KirkbyJane A Mitchell
Mar 5, 2019·Anti-cancer Agents in Medicinal Chemistry·Bahadır Bülbül, İlkay Küçükgüzel
May 10, 2016·Journal of Cardiovascular Pharmacology·Oreoluwa O Adedoyin, Charles D Loftin
Jun 25, 2019·Frontiers in Pharmacology·Filip BergqvistPer-Johan Jakobsson
Mar 15, 2019·Arthritis Research & Therapy·Filip BergqvistStephanie G Dakin
Dec 13, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sun-Hee KimElizabeth A Grimm
Jul 12, 2017·Bioorganic & Medicinal Chemistry Letters·Ziyuan ZhouChang-Guo Zhan
Jun 9, 2021·The Journal of Clinical Investigation·Soon Y TangGarret A FitzGerald

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.